The TOR pathway: a target for cancer therapy - PubMed (original) (raw)

Review

doi: 10.1038/nrc1362.

Affiliations

• PMID: 15122205
• DOI: 10.1038/nrc1362

Review

The TOR pathway: a target for cancer therapy

Mary-Ann Bjornsti et al. Nat Rev Cancer. 2004 May.

No abstract available

PubMed Disclaimer

Similar articles

• Retroviral oncogenes and TOR.
  Aoki M, Vogt PK. Aoki M, et al. Curr Top Microbiol Immunol. 2004;279:321-38. doi: 10.1007/978-3-642-18930-2_19. Curr Top Microbiol Immunol. 2004. PMID: 14560966 Review.
• Current status and challenges associated with targeting mTOR for cancer therapy.
  Dowling RJ, Pollak M, Sonenberg N. Dowling RJ, et al. BioDrugs. 2009;23(2):77-91. doi: 10.2165/00063030-200923020-00002. BioDrugs. 2009. PMID: 19489650 Review.
• Prospects for mTOR targeting in adult T cell leukemia.
  Altman JK, Platanias LC. Altman JK, et al. Leuk Lymphoma. 2009 Apr;50(4):525-6. doi: 10.1080/10428190902741505. Leuk Lymphoma. 2009. PMID: 19373648 No abstract available.
• mTOR inhibition and adult T-cell leukemia.
  Hirase C, Maeda Y, Yamaguchi T, Miyatake J, Kanamaru A. Hirase C, et al. Leuk Lymphoma. 2009 Apr;50(4):645-7. doi: 10.1080/10428190802709446. Leuk Lymphoma. 2009. PMID: 19373664 No abstract available.
• [Advances on PI3K/Akt/mTOR signalling pathway in malignancies].
  Yu BH, Zhou XY. Yu BH, et al. Zhonghua Bing Li Xue Za Zhi. 2005 Oct;34(10):674-6. Zhonghua Bing Li Xue Za Zhi. 2005. PMID: 16536284 Review. Chinese. No abstract available.

Cited by

• Pathophysiology of Arginases in Cancer and Efforts in Their Pharmacological Inhibition.
  Marzęta-Assas P, Jacenik D, Zasłona Z. Marzęta-Assas P, et al. Int J Mol Sci. 2024 Sep 10;25(18):9782. doi: 10.3390/ijms25189782. Int J Mol Sci. 2024. PMID: 39337272 Free PMC article. Review.
• Molecular precision medicine: Multi-omics-based stratification model for acute myeloid leukemia.
  Wang T, Cui S, Lyu C, Wang Z, Li Z, Han C, Liu W, Wang Y, Xu R. Wang T, et al. Heliyon. 2024 Aug 20;10(17):e36155. doi: 10.1016/j.heliyon.2024.e36155. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39263156 Free PMC article.
• TIPRL, a Potential Double-edge Molecule to be Targeted and Re-targeted Toward Cancer.
  Gao J, You T, Liu J, Yang L, Liu Y, Wang Y. Gao J, et al. Cell Biochem Biophys. 2024 Sep;82(3):1681-1691. doi: 10.1007/s12013-024-01334-5. Epub 2024 Jun 18. Cell Biochem Biophys. 2024. PMID: 38888871 Review.
• Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma.
  Yang S, Yang X, Hou Z, Zhu L, Yao Z, Zhang Y, Chen Y, Teng J, Fang C, Chen S, Jia M, Liu Z, Kang S, Chen Y, Li G, Niu Y, Cai Q. Yang S, et al. Heliyon. 2024 Apr 4;10(7):e29215. doi: 10.1016/j.heliyon.2024.e29215. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38623200 Free PMC article. Review.
• Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review.
  Wang L, Qiu Q, Yang D, Cao C, Lu Y, Zeng Y, Jiang W, Shen Y, Ye Y. Wang L, et al. Front Pharmacol. 2024 Mar 22;15:1173240. doi: 10.3389/fphar.2024.1173240. eCollection 2024. Front Pharmacol. 2024. PMID: 38584599 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations

• Molecular Biology Databases

  • Saccharomyces Genome Database

• Miscellaneous

  • NCI CPTAC Assay Portal